Morphine, gabapentin, or their combination for neuropathic pain

被引:697
作者
Gilron, I
Bailey, JM
Tu, DS
Holden, RR
Weaver, DF
Houlden, RL
机构
[1] Queens Univ, Dept Anesthesiol, Kingston, ON K7L 2V7, Canada
[2] Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 2V7, Canada
[3] Queens Univ, Dept Math & Stat, Kingston, ON K7L 2V7, Canada
[4] Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON K7L 2V7, Canada
[5] Queens Univ, Dept Psychol, Kingston, ON K7L 2V7, Canada
[6] Queens Univ, Dept Med, Div Endocrinol, Kingston, ON K7L 2V7, Canada
[7] Dalhousie Univ, Dept Med, Div Neurol, Halifax, NS, Canada
[8] Dalhousie Univ, Dept Chem, Halifax, NS, Canada
关键词
D O I
10.1056/NEJMoa042580
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The available drugs to treat neuropathic pain have incomplete efficacy and dose-limiting adverse effects. We compared the efficacy of a combination of gabapentin and morphine with that of each as a single agent in patients with painful diabetic neuropathy or postherpetic neuralgia. Methods: In this randomized, double-blind, active placebo-controlled, four-period crossover trial, patients received daily active placebo (lorazepam), sustained-release morphine, gabapentin, and a combination of gabapentin and morphine - each given orally for five weeks. The primary outcome measure was mean daily pain intensity in patients receiving a maximal tolerated dose; secondary outcomes included pain (rated according to the Short-Form McGill Pain Questionnaire), adverse effects, maximal tolerated doses, mood, and quality of life. Results: Of 57 patients who underwent randomization (35 with diabetic neuropathy and 22 with postherpetic neuralgia), 41 completed the trial. Mean daily pain (on a scale from 0 to 10, with higher numbers indicating more severe pain) at a maximal tolerated dose of the study drug was as follows: 5.72 at baseline, 4.49 with placebo, 4.15 with gabapentin, 3.70 with morphine, and 3.06 with the gabapentin-morphine combination (P<0.05 for the combination vs. placebo, gabapentin, and morphine). Total scores on the Short-Form McGill Pain Questionnaire (on a scale from 0 to 45, with higher numbers indicating more severe pain) at a maximal tolerated dose were 14.4 with placebo, 10.7 with gabapentin, 10.7 with morphine, and 7.5 with the gabapentin-morphine combination (P<0.05 for the combination vs. placebo, gabapentin, and morphine). The maximal tolerated doses of morphine and gabapentin were lower (P<0.05) with the combination than for each drug as single agent. At the maximal tolerated dose, the gabapentin-morphine combination resulted in a higher frequency of constipation than gabapentin alone (P<0.05) and a higher frequency of dry mouth than morphine alone (P<0.05). Conclusions: Gabapentin and morphine combined achieved better analgesia at lower doses of each drug than either as a single agent, with constipation, sedation, and dry mouth as the most frequent adverse effects.
引用
收藏
页码:1324 / 1334
页数:11
相关论文
共 34 条
  • [1] Agresti A., 1990, Analysis of categorical data
  • [2] [Anonymous], 1987, MULTIPLE COMP PROCED, DOI DOI 10.1002/9780470316672
  • [3] Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus - A randomized controlled trial
    Backonja, M
    Beydoun, A
    Edwards, KR
    Schwartz, SL
    Fonseca, V
    Hes, M
    LaMoreaux, L
    Garofalo, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (21): : 1831 - 1836
  • [4] BECK AT, 1993, BECK DEPRESSION INEN
  • [5] Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin
    Carlton, SM
    Zhou, ST
    [J]. PAIN, 1998, 76 (1-2) : 201 - 207
  • [6] Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
  • [7] Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain
    Dellemijn, PLI
    Vanneste, JAL
    [J]. LANCET, 1997, 349 (9054) : 753 - 758
  • [8] DICKENSON AH, 1994, PROGR PAIN RES MANAG, V2
  • [9] Advances in neuropathic pain - Diagnosis, mechanisms, and treatment recommendations
    Dworkin, RH
    Backonja, M
    Rowbotham, MC
    Allen, RR
    Argoff, CR
    Bennett, GJ
    Bushnell, MC
    Farrar, JT
    Galer, BS
    Haythornthwaite, JA
    Hewitt, DJ
    Loeser, JD
    Max, MB
    Saltarelli, M
    Schmader, KE
    Stein, C
    Thompson, D
    Turk, DC
    Wallace, MS
    Watkins, LR
    Weinstein, SM
    [J]. ARCHIVES OF NEUROLOGY, 2003, 60 (11) : 1524 - 1534
  • [10] Gabapentin enhances the analgesic effect of morphine in healthy volunteers
    Eckhardt, K
    Ammon, S
    Hofmann, U
    Riebe, A
    Gugeler, N
    Mikus, G
    [J]. ANESTHESIA AND ANALGESIA, 2000, 91 (01) : 185 - 191